A Clinical Trial of Bio-Germanium for the Evaluation of Efficacy on Immune Function — NYG

Normal Healthy Subjects Clinical Trial

Official title:
A Clinical Trial of Bio-Germanium for the Evaluation of Efficacy on Immune Function Enhancement and Immune Cell Activation

Status Completed

Clinical Trial Summary

This study is a 8-week, randomized, double-blind, placebo-controlled clinical trial of Bio-Germanium for the evaluation of efficacy on immune function and immune cell activation.

Clinical Trial Description

This study will evaluate Bio-Germanium's efficacy on immune function and immune cell activation in healthy volunteers by assessing improvements in certain immune indices (i.e. NK cell activity, WBC, IFN-γ, TNF-α, IgG1, IgG2, IgM, IL-2, 6, 12). ;

Study Design

Related Conditions & MeSH terms

Normal Healthy Subjects

Clinical Trial Details

NCT number	NCT03677921
Study type	Interventional
Source	Yonsei University
Contact
Status	Completed
Phase	N/A
Start date	December 10, 2017
Completion date	September 10, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03739970` - A Clinical Trial of Silk Peptide for the Evaluation of Efficacy on Immune Function	N/A
Completed	`NCT01941446` - A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization	Phase 1
Completed	`NCT05447546` - Study to Evaluate HT-6184 in Healthy Subjects	Phase 1
Completed	`NCT01652859` - An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects	Phase 1